A pharmaceutical composition comprising a compound of Formula I-I: or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of NH, O, and S, wherein the hydrogen of NH may be substituted with R 3; Y is selected from N and CH, wherein the hydrogen of CH may be substituted with R 3; Z is selected from N and CH, wherein the hydrogen of CH may be substituted with R 3, or Z is C when Z is substituted with the -C N(R 2)- moiety; R 1 is selected from the group consisting of -Cl, -F, and C 1-6 alkyl substituted with one or more substituents independently selected from -Cl and -F, preferably wherein R 1 is -Cl, -F, or -CF 3; R 2 is hydrogen; each R 3 is independently selected from the group consisting of halogen, C 1-6 alkyl, C 1- 6 heteroalkyl, C 3 - 7 cycloalkyl, 3-7 membered heterocyclyl, -S 2 NR 4 R 5, -NR 4 S R 6, - C NR 4 R 5, -S 2 R 6, and -O-R 6, wherein C 1-6 alkyl is optionally substituted with one or more substituents independently selected from halogen, -NR 4 R 5, and -S 2 R 6; n is selected from the group consisting of 0, 1, 2, 3, and 4; R 4 and R 5 are each independently hydrogen or C 1-6 alkyl, wherein C 1-6 alkyl is optionally substituted with oxo; or R 4 and R 5 may be taken together with the nitrogen to which R 4 and R 5 are attached to form a 4-7 membered heterocyclyl optionally substituted with one or more substituents independently selected from halogen, -OH, C 1-6 alkyl, and C 1- 6 heteroalkyl; each R 6 is independently selected from the group consisting of C 1-6 alkyl, C 1-6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, and benzyl; and s is 1 or 2; and a pharmaceutically acceptable excipient. X is selected from the group consisting of NH, O, and S, wherein the hydrogen of NH may be substituted with R 3; Y is selected from N and CH, wherein the hydrogen of CH may be substituted with R 3; Z is selected from N and CH, wherein the hydrogen of CH may be substituted with R 3, or Z is C when Z is substituted with the -C N(R 2)- moiety; Y is selected from N and CH, wherein the hydrogen of CH may be substituted with R 3; Z is selected from N and CH, wherein the hydrogen of CH may be substituted with R 3, or Z is C when Z is substituted with the -C N(R 2)- moiety; R 1 is selected from the group consisting of -Cl, -F, and C 1-6 alkyl substituted with one or more substituents independently selected from -Cl and -F, preferably wherein R 1 is -Cl, -F, or -CF 3; R 2 is hydrogen; each R 3 is independently selected from the group consisting of halogen, C 1-6 alkyl, C 1- 6 heteroalkyl, C 3 - 7 cycloalkyl, 3-7 membered heterocyclyl, -S 2 NR 4 R 5, -NR 4 S R 6, - C NR 4 R 5, -S 2 R 6, and -O-R 6, wherein C 1-6 alkyl is optionally substituted with one or more substituents independently selected from halogen, -NR 4 R 5, and -S 2 R 6; n is selected from the group consisting of 0, 1, 2, 3, and 4; R 4 and R 5 are each independently hydrogen or C 1-6 alkyl, wherein C 1-6 alkyl is optionally substituted with oxo; or R 4 and R 5 may be taken together with the nitrogen to which R 4 and R 5 are attached to form a 4-7 membered heterocyclyl optionally substituted with one or more substituents independently selected from halogen, -OH, C 1-6 alkyl, and C 1- 6 heteroalkyl; each R 6 is independently selected from the group consisting of C 1-6 alkyl, C 1-6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, and benzyl; and s is 1 or 2;